Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
Placebo Phase 3 Results Expected
Placebo • NASH/MASH
Target Indication
NASH/MASH
Clinical Trial
Last updated: 12/4/2025
AKRO
Akero Therapeutics, Inc.